It is a new wearable device for continuous glucose monitoring, recently presented at the ATTD (Advanced Technologies & Treatments for Diabetes) international conference held in Florence. The device combines a sensor and transmitter and is intended for individuals undergoing insulin therapy from the age of two. It includes innovative features for increasingly personalized and accessible therapy management: it measures and automatically sends glucose readings wirelessly to a compatible smartphone, receiver, or smartwatch, eliminating the need for finger pricks or scans. Thanks to the dedicated app, users can view glucose trend directions, set customizable alerts for threshold values, log events such as food intake, physical activity, and insulin doses, and share data. It can be worn on the arm or abdomen and, for children aged 2 to 6 years, also on the upper buttocks, providing greater discretion. It is also water-resistant, withstanding prolonged water contact for up to 24 hours and at depths of up to 2.4 meters.
Early diagnosis of breast cancer with liquid biopsy: now you can
With 2.1 million new diagnoses worldwide in 2018, breast cancer is the most prevalent neoplasm in the female population globally, but also the one that can be cured best, often
